CARBIDOPA PHARMACOPOEIA européenne (EP) R

Non disponible en dehors du Royaume-Uni et de l'Irlande

Caution

Please find SDS provided by EDQM here..

General description

Carbidopa is a dopaminergic drug, which is known to inhibit the conversion of dopa to dopamine. It is used in combination with levodopa for the effective treatment of restless legs syndrome and periodic leg movements in sleep.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

Unit quantity: 50 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.